Keyword Search
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/11/14Syros Pharmaceuticals Presents New Data from Its Gene Control Platform at Oncology Conferences
- Posters at 56th ASH Annual Meeting and 2014 San Antonio Breast Cancer Symposium highlight identification of patient subtypes and novel drug targets in acute myeloid leukemia and breast cancer -WATERTOWN, MA, December 11, 2014 – Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, announced today that data demonstrating the use of Syros’ gene control platform to detect and characterize gene control elements directly from patient tissu... 
Printer Friendly Version
12/11/14Syros Pharmaceuticals Announces New Research Published on CDK7 in Lung and Pediatric Cancers
- Papers in Cell and Cancer Cell describe in vivo activity of CDK7 inhibitors; further validate company’s lead preclinical program  -WATERTOWN, MA, December 11, 2014 – Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, announced today the recent publication of two studies that further demonstrate the critical role of CDK7 in cancers driven by oncogenic transcription factors, including certain lung and pedi... 
Printer Friendly Version
11/06/14Syros Pharmaceuticals’ Scientists Publish New Method to Detect Epigenomic Changes Following Drug Treatment
- Paper in Cell Reports describes ChIP-Rx, a novel approach to measure how drugs alter gene control programs -WATERTOWN, MA, November 6, 2014 – Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, announced today that its scientists have developed an important new approach to measuring cell specific and pharmacologic changes in gene control elements, allowing for precise and direct comparative analysis. This novel method addr... 
Printer Friendly Version
10/27/14Syros Pharmaceuticals Closes $53 Million Series B Financing
- Includes Leading Public and Healthcare-Focused Funds - - Proceeds Will Accelerate Gene Control Programs and Platform -WATERTOWN, MA, October 27, 2014 – Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies in cancer and other diseases, announced today that it has closed its Series B round with $53 million in new investment. The proceeds from this financing will be used to advance the company’s portfolio of cancer programs to... 
Printer Friendly Version
10/27/14GREECE-ING THE CLINICAL SKIDS Neighborhood watch: Gene maps get 'Syros,' draw $53M series B; BioWorld. Osbourne, Randy
... 
Printer Friendly Version
10/27/14Syros Raises $53M More To Push Gene-Control Drugs Into Human Trials; Xconomy. Lash, Alex
... 
Printer Friendly Version
10/14/14Syros Pharmaceuticals’ Scientific Founders Publish New Research on Gene Control Mechanisms
- Papers in Cell and Molecular Cell expand on importance of super-enhancers in regulating gene expression in normal and inflammatory statesWATERTOWN, MA, October 14, 2014 – Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, announced today that recently published research from two of its scientific founders sheds new light on the crucial role of gene control mechanisms in cellular function. In the Cell paper “Control of ... 
Printer Friendly Version
09/23/14Syros Pharmaceuticals Presents Research on Gene Control in Acute Myeloid Leukemia at AACR Hematologic Malignancies Meeting
- Data Indicate that Syros’ Leading Gene Control Platform Can Uncover Cancer Drivers and New Target Opportunities for Potential Treatments -  WATERTOWN, MA, September 23, 2014 – Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, announced today presentation of research at the American Association of Cancer Research (AACR) Hematologic Malignancies Meeting that highlights gene control as an approach to treating cancer, op... 
Printer Friendly Version
07/24/14Selecting CDK7; SCIBX. Can, Chris
... 
Printer Friendly Version
06/23/14Syros Pharmaceuticals Co-Founders’ Novel Approach to Cancer Regulation Published in Nature
Discovery further validates Syros’ proprietary gene control platformWATERTOWN, MA, June 23, 2014– Syros Pharmaceuticals, a therapeutics company harnessing breakthroughs in gene control to discover and develop revolutionary drugs to treat cancer and other diseases, announced today the publication of a study analyzing the critical role of CDK7 inhibitors in regulating cancer-causing genes. Led by Syros Scientific Co-Founders Nathanael S. Gray, Ph.D., and Richard A. Young, Ph.D., the paper en... 
Printer Friendly Version
06/10/14Syros Pharmaceuticals Appoints Genomics Entrepreneur Jorge Conde to Dual Role as Chief Financial Officer and Chief Product Officer
WATERTOWN, MA, June 10, 2014 – Syros Pharmaceuticals, a therapeutics company harnessing breakthroughs in gene control to discover and develop revolutionary drugs to treat cancer and other diseases, announced today that Jorge Conde has joined Syros’ executive leadership team as its Chief Financial Officer (CFO) and Chief Product Officer. Mr. Conde will lead the platform strategy for Syros’ novel gene regulation technology and manage the overall finances for the company.   Prio... 
Printer Friendly Version
04/02/14Richard A. Young, Syros Pharmaceuticals Scientific Founder, to Open AACR Annual Meeting 2014 with Address Highlighting His Pioneering Gene Control Research
- Dr. Young’s Research Underscores a Growing Focus in Harnessing Gene Control to Address the Underlying Mechanisms of Cancer for Improved Therapies -WATERTOWN, MA, April 2, 2014 – Syros Pharmaceuticals, a life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases, announced today that one of its scientific co-founders, Richard A. Young, Ph.D., will give the opening address at the American Association for Cancer Resear... 
Printer Friendly Version
03/10/14Nature Biotechnology's academic spinouts of 2013; Nature Biotechnology. Bouchie, Aaron; Allison, Malorye; Webb, Sarah; DeFrancesco
... 
Printer Friendly Version